David Thompson

Corporate Officer/Principal presso INOZYME PHARMA, INC.

Consumer Services

Health Technology

Profilo

David Thompson is the founder of Azure Biotech, Inc. He is currently a Member-Scientific Advisory Board & Senior Advisor at Inozyme Pharma, Inc. His former position at Inozyme Pharma, Inc. was Chief Scientific Officer & Senior Vice President from 2018 to 2020.
Dr. Thompson has a graduate and doctorate degree from the University of Connecticut and a graduate degree from The University of Montana.

Posizioni attive di David Thompson

Società	Posizione	Inizio
INOZYME PHARMA, INC.	Corporate Officer/Principal	01/07/2021

Tutte le posizioni attive di David Thompson

Precedenti posizioni note di David Thompson

Società	Posizione	Fine
INOZYME PHARMA, INC.	Chief Tech/Sci/R&D Officer	13/10/2020
Azure Biotech, Inc. Azure Biotech, Inc. BiotechnologyHealth Technology Azure Biotech, Inc. is a private biotechnology company that is developing an alternative product to address the many drawbacks of current therapies for vulvovaginal atrophy (VVA). The company is based in New York, NY. The company has the exclusive worldwide rights to all topical formulations of lasofoxifene, a selective estrogen receptor modulator (SERM). Azure plans to rapidly build upon the extensive safety and efficacy data already available from clinical trials previously completed with an oral formulation in more than 15,000 women. The company was founded by David Thompson.	Founder	-

Vedi nel dettaglio l'esperienza di David Thompson

Formazione di David Thompson

University of Connecticut	Doctorate Degree
The University of Montana	Graduate Degree

Esperienze
Posizioni ricoperte

Attive

Inattive

Società quotate in Borsa

Aziende private

Vedi nel dettaglio l'esperienza di David Thompson

Relazioni

Relazioni di 1° grado

Aziende connesse in 1º grado

Uomo

Donna

Amministratori

Dirigenti

Vedi i contatti personali

Società collegate

Società quotate in Borsa	1
INOZYME PHARMA, INC.	Health Technology

Aziende private	1
Azure Biotech, Inc. Azure Biotech, Inc. BiotechnologyHealth Technology Azure Biotech, Inc. is a private biotechnology company that is developing an alternative product to address the many drawbacks of current therapies for vulvovaginal atrophy (VVA). The company is based in New York, NY. The company has the exclusive worldwide rights to all topical formulations of lasofoxifene, a selective estrogen receptor modulator (SERM). Azure plans to rapidly build upon the extensive safety and efficacy data already available from clinical trials previously completed with an oral formulation in more than 15,000 women. The company was founded by David Thompson.	Health Technology